

**QIBA Volumetric CT Group 3A Update**  
Thursday, 18 September 2014 at 11:30 AM CT  
Call Summary

**In attendance**

*Maria Athelougou, PhD (Chair)*  
Hubert Beaumont, PhD  
Andrew Buckler, MS  
Heang-Ping Chan, PhD

Lubomir Hadjiiski, PhD  
Rudresh Jarecha, MBBS  
Nancy Obuchowski, PhD  
Adele Peskin, PhD

Nicholas Petrick, PhD  
Daniel Sullivan, MD  
Ying Tang, PhD  
Amit Vasanthi, PhD

**RSNA**

Julie Lisiecki  
Madeleine McCoy

**Update: Paper for the Pivotal Phantom Challenge**

- The manuscript is with *Interventional Radiology* for review

**Update: Paper for the Clinical Challenge**

- Review is ongoing at both NIST and the FDA.

**Proposed Vendor Independent Manuscript Based on the QIBA 3A Clinical Challenge**

- Dr. Beaumont outlined his idea to self-identify and publish his company's results for the clinical study
- 3A Group feedback and suggestions invited
  - Dr. Athelougou commented that such a paper would be a "multiplier of the group's work"
  - Dr. Jarecha also responded favorably
  - Mr. Buckler added that no other vendors would be identified in Dr. Beaumont's paper, maintaining the rankings of anonymized algorithm performance via the community benchmark
    - If a vendor's algorithm performed well, publication could be a significant marketing strategy
- Some challenges were identified:
  - Publishing ahead of the overall study manuscript may "steal the thunder" of the 3A Challenge results
  - A paper and poster have been deemed acceptable with the understanding that only the individual vendor's results would be discussed, not a comparison to the main study group.
    - QIBA 3A challenge participants are asked to share insights: [andrew.buckler@elucidbio.com](mailto:andrew.buckler@elucidbio.com); [mathelougou@definiens.com](mailto:mathelougou@definiens.com)

**Next Steps for Group 3A**

- Discussion regarding whether Group 3A should propose and conduct a "field test" for testing Profile compliance
  - Additional data would be needed, along with sample size augmentation, and sequestration of some data for compliance testing at a later date.
  - It was determined that such an undertaking must be initiated and conducted by the parent QIBA Technical Committee, as Group 3A does not have the resources.
- The group is considering challenge options; suggestions welcome to Dr. Athelougou: [Mathelougou@definiens.com](mailto:Mathelougou@definiens.com).

**Action items:**

- Practical suggestions for the future work of Group 3A to be sent to Dr. Athelougou: [Mathelougou@definiens.com](mailto:Mathelougou@definiens.com).

---

**Next call:** Thursday, **October 2, 2014** at 11:30 AM CT.